Skip to content

RNTX RNTX Cash & Equivalents

Cash & Equivalents at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$9.57B-12.0%
Gilead Sciences logo
Gilead SciencesGILD
$7.63B-3.8%
AbbVie logo
AbbVieABBV
$9.39B+81.5%
CTO
Citius Oncology, Inc.CTOR
$2.63M+2,350,466%
Ethos Technologies, Inc.
 logo
Ethos Technologies, Inc. LIFE
$10.01M-3.4%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$37.5M+149%

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M+6.8%
Net income-$5.8M-6.1%
EPS (diluted)-$0.19+24.0%

Balance sheet

See full
Total debt$48.0K0.0%
Total equity$6.9M-63.0%
Total assets$26.3M-54.4%

Cash flow

See full
Operating cash flow-$3.4M+44.6%
CapEx-
Free cash flow-$6.3M

Valuation

See full
Market cap$88.96M+177%

Returns & leverage

See full
Return on equity-123.3%+86.1pp
Debt / equity0.0×
Current ratio0.4×-1.0×

Where this comes from

Reported directly by RNTX in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: RNTX’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about RNTX's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RNTX's cash & equivalents?
RNTX (RNTX) reported cash & equivalents of $4.45M in Q1 2026.
How has RNTX's cash & equivalents changed year-over-year?
RNTX's cash & equivalents decreased by 40.2% year-over-year, from $7.43M to $4.45M.
What is the long-term trend for RNTX's cash & equivalents?
Over 5 years (2020 to 2025), RNTX's cash & equivalents has grown at a -14.5% compound annual growth rate (CAGR), from $7.05M to $3.22M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.